Efficacy, tolerability and cosmetic acceptabilily of Toléderm® in patients with inflammatory cutaneous diseases of the face

We performed an open-label clinical trial to assess the efficacy, tolerability and cosmetic acceptability of Toléderm® hydra-soothing cream, a new emulsion indicated for sensitive skin, in patients with mild to moderate inflammatory cutaneous diseases of the face. Forty patients (32 females and 8 males), aged 15-80 years (mean age: 38.5 years), with contact dermatitis (8), solar erythema (7), seborrheic dermatitis (6), psoriasis (5), atopic dermatitis (5), acne (5), vitiligo (2) and post-peeling erythema/scaling (2) were enrolled at the Department of Dermatology of the University of L'Aquila. Patients were treated with Toléderm® hydra-soothing cream for facial skin hydration, twice daily, for 4 weeks. The study included a screening visit and a treatment period with regular visits after 2 and 4 weeks. Clinical evaluation of erythema, xerosis, scaling and itching as well as instrumental assessment of cutaneous pH, skin hydration and sebum concentration were performed at each scheduled visit. All subjects completed a self-administered questionnaire for evaluation of cosmetologic characteristics of the study product. After treatment, a significant decrease of erythema, xerosis, scaling and itching was observed. Instrumental assessment showed an increase of skin hydration together with a decrease of erythema while values of cutaneous pH and sebum concentration remained stable during the entire study period. Self-administered questionnaires on cosmetic acceptability revealed an overall judgment of excellent or very good by all patients. In conclusion, our results demonstrate the efficacy, tolerability and cosmetic acceptability of Tolederm® hydra-soothing cream in patients with mild to moderate inflammatory cutaneous diseases of the face.